Status:
COMPLETED
SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare Symbicort Single Inhaler treatment with the Best Conventional Practice in patients with persistent asthma
Eligibility Criteria
Inclusion
- Diagnosis of asthma \< 3 months
- Prescribed daily use of glucocorticosteroids for at least 3 months prior to Visit 1
Exclusion
- Smoking history \> 10 pack-years
- Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to inclusion
- Any significant disease or disorder that my jeopardize the safety of the patient.
- Additional inclusion and exclusion criteria will be evaluated by the investigator.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
1300 Patients enrolled
Trial Details
Trial ID
NCT00238784
Start Date
May 1 2004
End Date
October 1 2005
Last Update
January 14 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aldergrove, British Columbia, Canada
2
Research Site
Bolton, Ontario, Canada
3
Research Site
Brampton, Ontario, Canada